Evidence map›Paper›PMID 33115867›Full record

ArticleJournal of virology2020

Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103

Steven A Yukl, Shahzada Khan, Tsui-Hua Chen, Martin Trapecar, Frank Wu, Guorui Xie, Sushama Telwatte, Daniel Fulop, Alexander R Pico, Gregory M Laird and 10 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Steven A Yukl *San Francisco Veterans Affairs Medical Center, San Francisco, California, USA steven.yukl@ucsf.edu Sanjabi.shomyseh@gene.com.ORCID 0000-0002-4578-9872
Shahzada Khan *Gladstone Institutes, San Francisco, California, USA.
Tsui-Hua ChenSan Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
Martin TrapecarGladstone Institutes, San Francisco, California, USA.
Frank WuGladstone Institutes, San Francisco, California, USA.
Guorui XieGladstone Institutes, San Francisco, California, USA.
Sushama TelwatteSan Francisco Veterans Affairs Medical Center, San Francisco, California, USA.ORCID 0000-0003-4086-5212
Daniel FulopGladstone Institutes, San Francisco, California, USA.
Alexander R PicoGladstone Institutes, San Francisco, California, USA.
Gregory M LairdAccelevir Diagnostics, Baltimore, Maryland, USA.ORCID 0000-0003-2873-4295
Kristen D RitterAccelevir Diagnostics, Baltimore, Maryland, USA.
Norman G JonesDepartment of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Chuanyi M LuSan Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nadia R RoanGladstone Institutes, San Francisco, California, USA.
Jeffrey M MilushDepartment of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Ma SomsoukDivision of Gastroenterology, University of California, San Francisco, San Francisco, California, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Peter W HuntDepartment of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California, USA.
Shomyseh SanjabiGladstone Institutes, San Francisco, California, USA steven.yukl@ucsf.edu Sanjabi.shomyseh@gene.com.
Gladstone Institutes · USUniversity of California, San Francisco · USSan Francisco VA Medical Center · USHoward Hughes Medical Institute · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT · 1988 to 2026
$93.6M
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruptionP01AI131374 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI PILLAI, SATISH KUMAR · 2017 to 2021
$8.5M
Training Program In Cellular and Molecular MedicineT32GM135457 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAJINI RAO · 2020 to 2026
$5.4M
Centralized Resource to Accurately Quantify Latent and Expressed HIV ReservoirsU24AI143502 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI LAIRD, GREGORY MICHAEL, MARTIN, ALBINE · 2020 to 2024
$4.9M
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1M
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologiesR01AI147777 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2019 to 2022
$3.8M
Characterizing HIV latent reservoir in vivoDP2AI112244 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI SANJABI, SHOMYSEH · 2013 to 2013
$2.8M
Investigating Mechanisms of HIV Persistence in the GutR01DK108349 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI YUKL, STEVEN A · 2015 to 2019
$2.2M
Elucidating the mechanism of progesterone-induced permissivity in the upperfemale reproductive tractR01AI127219 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2016 to 2020
$2.1M
A Novel Test to Measure Latent Virus in HIV-1 Infected PatientsR44AI124996 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI LAIRD, GREGORY MICHAEL · 2018 to 2019
$2.0M
Understanding HIV latency reversal and clearance of infected cells in vivoR01AI132128 · NIAID · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WONG, JOSEPH K, YUKL, STEVEN A · 2017 to 2021
$1.9M
BD FACSAria II Flow CytometerS10RR028962 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI CAVROIS, MARIELLE · 2011 to 2011
$544k
NCRR NIH HHS S10 RR028962NIAID NIH HHS DP2 AI112244NIAID NIH HHS P01 AI131374NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI127219NIAID NIH HHS R01 AI132128NIAID NIH HHS R01 AI147777NIAID NIH HHS R44 AI124996NIAID NIH HHS U24 AI143502NIDDK NIH HHS R01 DK108349NIDDK NIH HHS R01 DK120387NIGMS NIH HHS T32 GM135457
6 · The paper itself

Abstract

Latent HIV infection is the main barrier to cure, and most HIV-infected cells reside in the gut, where distinct but unknown mechanisms may promote viral latency. Transforming growth factor β (TGF-β), which induces the expression of CD103 on tissue-resident memory T cells, has been implicated in HIV latency. Using CD103 as a surrogate marker to identify cells that have undergone TGF-β signaling, we compared the HIV RNA/DNA contents and cellular transcriptomes of CD103

Indexed as

Antigens, CDAntiviral AgentsCD4-Positive T-LymphocytesDNA, ViralGastrointestinal TractGene Expression RegulationHIV-1HIV InfectionsHumansIntegrin alpha ChainsIntraepithelial LymphocytesProvirusesRibosomal ProteinsRNA, ViralT-Lymphocyte SubsetsTranscription, Geneticalpha E integrinsAntigens, CDAntiviral AgentsDNA, ViralIntegrin alpha ChainsRibosomal ProteinsRNA, ViralCD103CD4 T cellgamma delta T cellHIV-1human immunodeficiency virusintestineslatencyPD-1tissue-resident memory celltransforming growth factor receptors

Identifiers

PMID33115867
PMCPMC7944458
OpenAlexW3096135687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.